Mangoceuticals Closes Registered Direct Offering Priced at 74% Premium to Recent Market Close
Key Highlights
- ➤$500,000 registered direct offering closed at $0.75 per unit
- ➤Offering price represents a 74% premium to recent $0.43 close
- ➤$2.5 million MangoRx IP strategic investment commitments include 25% subsidiary stake
- ➤MangoRx IP received $1.75 million; remaining $750,000 due November 28
- ➤Warrants accompanying shares could result in potential dilution
Expert Statements
Jacob D. Cohen, Chief Executive Officer of Mangoceuticals
“We believe the ability to attract a direct investment at a substantial premium to our recent trading price, shortly after securing strategic capital commitments for MangoRx IP, is an encouraging development for Mangoceuticals.”
Jacob D. Cohen, Chief Executive Officer of Mangoceuticals
“These transactions demonstrate our focus on pursuing financing structures suited to different parts of our business.”
Jacob D. Cohen, Chief Executive Officer of Mangoceuticals
“We intend to build on this momentum as we advance commercialization initiatives and evaluate opportunities to create long-term shareholder value.”
Transaction follows a $2.5 million strategic investment commitment at MangoRx IP Holdings to support intellectual property commercialization
DALLAS, TX, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”), a company focused on developing, marketing and selling health and wellness products through its telemedicine platforms under the MangoRx and PeachesRx brands, today announced the closing of a registered direct offering with a U.S.-based private investment firm, priced at a premium to the Company’s recent closing share price. Management believes the transaction reflects investor interest in the Company’s strategy and long-term opportunities.
Get started
Create a free account to read the full story.